SEATTLE--(BUSINESS WIRE)--Northstar Neuroscience, Inc. (NASDAQ: NSTR), a developer of medical devices for the treatment of neurological diseases and disorders, today announced promising initial data from an eight patient feasibility study (CHESTNUT) of cortical stimulation to treat stroke-related Broca's aphasia. The study's principal investigators found that investigational cortical stimulation in combination with intensive speech-language therapy may result in greater language improvement for chronic Broca’s aphasia than speech-language therapy alone. These findings are being presented today at the American Congress of Rehabilitation Medicine / American Society of Neurorehabilitation Joint Educational Conference in Boston.
